Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» prostate cancer
prostate cancer
Bayer says 2024 sales of prostate cancer drug above $1 bln
Reuters
Thu, 03/21/24 - 10:58 am
Bayer
prostate cancer
Nubeqa
Promontory’s prostate cancer trial reaches patient enrolment milestone
Clinical Trials Arena
Mon, 03/11/24 - 11:41 am
Promontory Therapeutics
clinical trials
PT-112
metastatic castration-resistant prostate cancer
prostate cancer
AI identifies New Type Of Prostate Cancer
Forbes
Thu, 02/29/24 - 06:51 pm
prostate cancer
artificial intelligence
Janux shares triple on early cancer immunotherapy data
BioPharma Dive
Wed, 02/28/24 - 11:08 am
Janux Therapeutics
clinical trials
solid tumors
prostate cancer
T-cell engager
Eli Lilly’s Verzenio fails prostate cancer test as possible Novartis showdown nears
Fierce Pharma
Wed, 02/7/24 - 11:26 am
Eli Lilly
Verzenio
prostate cancer
Pfizer funnels $15M into 3-year ACS initiative designed to tackle cancer care disparities
Fierce Biotech
Mon, 02/5/24 - 10:23 am
Pfizer
American Cancer Society
clinical trials
pharma marketing
breast cancer
prostate cancer
CellVax receives FDA clearance for prostate cancer drug trial
Clinical Trials Arena
Tue, 01/30/24 - 10:47 am
CellVax Therapeutics
FDA
FK-PC101
prostate cancer
clinical trials
Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street
BioSpace
Mon, 12/18/23 - 10:14 pm
Point Biopharma
Lantheus Holdings
radioligands
prostate cancer
Eli Lilly
Xtandi cleared by FDA for earlier-stage prostate cancer
Pharmaphorum
Fri, 11/17/23 - 10:10 am
Pfizer
Astellas
Xtandi
prostate cancer
FDA
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Thu, 11/16/23 - 11:45 am
Astellas
Propella Therapeutics
M&A
JNJ
Zytiga
prostate cancer
Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data
BioSpace
Tue, 10/24/23 - 09:54 am
ESMO
Novartis
prostate cancer
Pluvicto
radiopharmaceuticals
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
Fierce Biotech
Mon, 10/23/23 - 10:33 am
ESMO
Ambrx
prostate cancer
ARX517
antibody-drug conjugate
EU clears review of Xtandi in earlier-stage prostate cancer
Pharmaphorum
Wed, 09/13/23 - 06:02 pm
EMA
Europe
Astellas
Pfizer
prostate cancer
Xtandi
Astellas withdraws lawsuit challenging Medicare drug price negotiation plans
Reuters
Thu, 09/7/23 - 10:44 am
Astellas
Medicare
prostate cancer
Xtandi
drug pricing
Inflation Reduction Act
Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer
Clinical Trials Arena
Mon, 08/21/23 - 10:02 am
Exelixis
Ipsen
Carbometyx
prostate cancer
Arcus and Gilead terminate development for etrumadenant in prostate cancer
Clinical Trials Arena
Tue, 08/8/23 - 10:36 pm
Arcus Biosciences
Gilead Sciences
prostate cancer
etrumadenant
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
Astellas to withhold prostate cancer drug from contract pharmacies
Beckers Hospital Review
Thu, 07/6/23 - 10:03 pm
Astellas
340B
Xtandi
prostate cancer
Sanofi blocks Sandoz's Jevtana generic in patent win
Fierce Pharma
Fri, 06/30/23 - 10:16 am
Sanofi
Jevtana
generics
Sandoz
prostate cancer
legal
Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med
Fierce Pharma
Thu, 06/22/23 - 10:12 am
Pfizer
FDA
prostate cancer
Talzenna
AstraZeneca
PARP inhibitors
Merck
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »